ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

0RGI Cosmo Pharmaceuticals Nv

126.90
0.00 (0.00%)
02 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Cosmo Pharmaceuticals Nv LSE:0RGI London Ordinary Share NL0011832936 COSMO PHARMACEUTICALS ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 126.90 47 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 103.99M 17.23M 0.9819 129.24 2.23B

Invitation to Cosmo's 2020 results / 2021 outlook presentation conference call on 26 March 2021

19/03/2021 9:00am

PR Newswire (US)


Cosmo Pharmaceuticals Nv (LSE:0RGI)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Cosmo Pharmaceuticals Nv Charts.

DUBLIN, March 19, 2021 /PRNewswire/ -- Cosmo Pharmaceuticals NV (SIX: COPN) invites investors, financial analysts and business/lifescience journalists for a telephone conference on 26 March 2021 with CEO Alessandro Della Chà and CFO Niall Donnelly to discuss the 2020 results and 2021 outlook of the company.

Cosmo Pharmaceuticals Logo

Date:  Friday, 26 March 2021
Time: 02:00 pm CET

Dial-in numbers:
Switzerland / Europe: +41 (0) 58 310 50 00
United Kingdom: +44 (0) 207 107 06 13
United States: +1 (1) 631 570 56 13

The presentation and press release as well as the Annual Report 2020 will be available for download as of 07:00 am CET on 26 March 2021 on www.cosmopharma.com

About Cosmo Pharmaceuticals

Cosmo is a specialty pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders and improve endoscopy quality measures through aiding the detection of colonic lesions. Cosmo has also developed medical devices for endoscopy and has recently entered into a partnership with Medtronic for the global distribution of GI Genius its artificial intelligence device for use in coloscopies and GI procedures. Cosmo has licensed Aemcolo® to Red Hill Biopharma Ltd. for the US and has licensed Relafalk® to Dr. Falk Gmbh for the EU and other countries. For additional information on Cosmo and its products please visit the Company's website: www.cosmopharma.com

Calendar
2020 Full Year Results and 2021 Outlook - March 26, 2021
Annual General Meeting, Amsterdam - May 28, 2021

 

 

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/invitation-to-cosmos-2020-results--2021-outlook-presentation-conference-call-on-26-march-2021-301250513.html

SOURCE Cosmo Pharmaceuticals N.V.

Copyright 2021 PR Newswire

1 Year Cosmo Pharmaceuticals Nv Chart

1 Year Cosmo Pharmaceuticals Nv Chart

1 Month Cosmo Pharmaceuticals Nv Chart

1 Month Cosmo Pharmaceuticals Nv Chart

Your Recent History

Delayed Upgrade Clock